Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab Phase 2a Dose Finding Study in Relapsing MS
NCT02738775Phase 2Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- May 2016
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ublituximab in multiple sclerosis (MS), sponsored by TG Therapeutics, Inc.. Started May 2016; status: completed.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02738775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02738775.